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AAV in SSc is described from the point of view of MPA. Some of reported SSc cases with AAV are thought to exhibit the
characteristic clinical manifestations of MPA, although ANCA positivity in SSc is uncommon. MPA is clinically characterized by a
multisystemicdiseasesuchasRPGN,pulmonaryhemorrhage,mononeuritis,andskininvolvement,aswellasothermanifestations
in conjunction with high levels of inﬂammatory activity such as high ESR or CRP. It is also characterized by a high frequency of
MPO-ANCA, showing predominant pANCA by IIF. When rapid renal failure or RPGN with active urine sediments, pulmonary
hemorrhage and/or systemic inﬂammatory manifestations are observed in patients with SSc having positive ANCA, the possibility
of MPA should always be considered. If SSc patients with MPA have life-threatening visceral involvement such as the above clinical
manifestations, the patients should be treated with induction therapy using cyclophosphamide, methotrexate, corticosteroids,
or plasmapheresis, etc. according to the severity of the disease soon after the diagnosis of MPA. It is important not to overlook
characteristic clinical manifestations of AAV during the course of the disease in SSc in order to diagnose MPA early.
1.Introduction
Systemic sclerosis (SSc), which mostly aﬀects middle-aged
women, is a chronic disorder of connective tissue charac-
terized by inﬂammation and ﬁbrosis and by degenerative
changes in the blood vessels, skin, synovium, skeletal muscle,
and certain internal organs, notably the gastrointestinal
tract, lung, heart, and kidney [1]. The life-threatening
visceral involvements in SSc include scleroderma renal crisis,
pulmonary hypertension, and lung ﬁbrosis.
On the other hand, microscopic polyangiitis (MPA),
which mostly aﬀects elderly people, is a systemic disease
characterized by vasculitis involving small blood vessels,
particularly the glomerular and pulmonary capillaries,
and serologically by antineutrophil cytoplasmic antibody
(ANCA) positivity [2–4] .M P Ai sa l s ow e l lk n o w nt op r e s e n t
as one form of primary ANCA-associated vasculitis (AAV)
as well as Wegener’s granulomatosis (WG) [2]. Clinical
manifestations in this disease include rapidly progressive
glomerulonephritis (RPGN) and pulmonary hemorrhage,
which are life-threatening visceral involvements.
Cases of SSc patients with AAV have been reported,
although ANCA positivity in SSc is uncommon. Some of
these cases are thought to exhibit the characteristic clinical
manifestations of MPA. In this paper, AAV in SSc will be
described from the point of view of MPA.
2.ANCA andMPA
ANCA is well known to be associated with small-sized
vasculitic disorders such as MPA, WG, and allergic granu-
lomatous angiitis (AGA) in primary systemic vasculitides.
These diseases are also known as primary ANCA-associated
vasculitides.TherearetwomajordistinctsubtypesofANCA.
Onesubtype is anantibody againstmyeloperoxidase (MPO),
which stains in a perinuclear pattern (pANCA) by indirect
immunoﬂuorescence (IIF) using a neutrophil substrate,
and the other subtype is an antibody against proteinase 3
(PR3), which stains in a diﬀuse granular cytoplasmic pat-
tern (cANCA) by IIF. Enzyme-linked immunosorbent assay
(ELISA) is used for target-speciﬁc ANCA determination [5].
MPO-ANCAcanbefoundinMPAandAGAmorefrequently
than in WG. On the other hand, PR3-ANCA is more speciﬁc
in WG than the other primary systemic vasculitides. The
association of MPA with MPO-ANCA is reported to be in2 International Journal of Rheumatology
Table 1: Comparison of clinical manifestations in MPA between French and Japanese studies.
French study [4] Japanese study [19]
Cases 85 63
Age, mean (range) years 56.8 (16–86) 59.0 (13–91)
Sex ratio, Male:Female 47 versus 38 19 versus 44
Fever 55.30% 71.00%
Weight loss 72.90% 42.90%
Skin involvement 62.40% 24.20%
Arthralgias 50.60% 62.90%
Myalgias 48.20% 50.80%
Renal involvement 78.80% 87.30%
Renal insuﬃciency (47/67) 70.1% 49.20%
Rapidly progressive GN — 66.70%
Proteinuria (54/67) 80.6% 93.10%
Hematuria (45/67) 67.2% 76.70%
Lung involvement 24.70% 63.50%
Alveolar hemorrhage 11.80% 22.20%
Pneumonitis 10.60% 33.30%
Pleiritis 5.90% 19.00%
Mononeuritis multiplex 57.60% 30.00%
Central nervous system involvement 11.80% 6.30%
Gastrointestinal tract involvement 30.60% 6.30%
Hypertension 34.10% 41.30%
Myocardial infarction 2.40% 1.60%
Pericariditis 10.60% 3.20%
Cardiac failure 17.60% 3.20%
therangeof40–80%, andMPAwithMPO-ANCAisnotedto
befrequentlyassociatedwithnecrotizingglomerulonephritis
and/or pulmonary capillaritis, namely, a pulmonary-renal
syndromesimilartothatobservedinGoodpasturesyndrome
or WG [3, 4]. Furthermore, renal-limited vasculitis, which
is characterized by pauci-immune focal necrotizing cres-
centic glomerulonephritis (pFNCGN), is classiﬁed as MPA
using European Medicines Agency (EMEA) algorithm [6].
Interestingly, MPO-ANCA-associated vasculitides are more
common in Asian countries than in the USA or Europe,
where 80% of AAV is PR-3 ANCA [6, 7] and ANCA-positive,
whileanti-MPO-negativepatientswithMPAmostoftenhave
antibody speciﬁcity for PR3 [3].
In Japan, MPO-ANCA has been reported to account for
90% of cases of AAV [8, 9]. Therefore, renal-limited AAV in
JapanisalmostexclusivelyMPA,whereasintheUKonly41%
of cases of renal limited AAV have MPA, although the overall
incidences of renal vasculitis are similar in the UK and Japan
[6].
On the other hand, ANCA has also been described
in patients with rheumatic autoimmune diseases, includ-
ing rheumatoid arthritis, systemic lupus erythemato-
sus, Sj¨ ogren’s syndrome, polymyositis/dermatomyositis, and
antiphospholipid syndrome. The ﬂuorescence patterns
encountered in these diseases are mostly pANCA. A
multitude of target antigens, including not only MPO
but also lactoferrin, elastase, lysozyme, cathepsin G, and
bactericidal/permeability-increasing protein (BPI) have been
described in rheumatic autoimmune diseases [3, 10]. How-
ever, ANCA in SSc is uncommon, showing a positive rate
ranging from 0 to 18% according to investigators [3, 11–17],
in spite of the development of many autoantibodies, such
as antitopoisomerase-I (Scl-70) antibodies, anticentromere
antibodies, and rheumatoid factors, in SSc. ANCA in SSc
usually shows pANCA and/or anti-MPO-ANCA, although
BPI and cathepsin G were reported to be the major antigenic
targets of ANCA seen in patients with SSc [18].
3.CharacteristicsofMPA
MPA is clinically characterized by a multisystemic disease
such as RPGN, alveolar hemorrhage, mononeuritis, and
skin involvement, as well as other manifestations. It is
also characterized by a high frequency of MPO-ANCA,
showing predominant pANCA by IIF as mentioned above.
Pathologically, inﬂammation and necrosis in various sites of
vessels including arteries, arterioles, capillaries, and venules
are observed, and pFNCGN characteristically occurs in
the context of MPA as well as WG. The severity of the
injury requires immediate treatment with immunosuppres-
sive drugs including cyclophosphamide and corticosteroids.
There are also some diﬀerences in the clinical mani-
festations of MPA, in addition to the clinical phenotype
of renal AVV, between Europe and Japan. Table 1 showsInternational Journal of Rheumatology 3
Table 2: Proposed diagnostic criteria for microscopic polyangiitis (MPA). (Research Committee on Intractable Vasculitis and Research
Committee on Epidemiology of Intractable Diseases, The Ministry of Health and Welfare of Japan, 1998).
(1) Clinical manifestations
(i) rapidly progressive glomerulonephritis
(ii) pulmonary hemorrhage or interstitial pneumonia
(iii) organ involvement besides kidney and lung:
purpura, subcutaneous bleeding, gastrointestinal bleeding, mononeuritis multiplex, and so forth
(2)Histological ﬁndings
necrotizing vasculitis in capillaries, venules, or arterioles, with perivascular inﬂammatory inﬁltrate
(3) Laboratory ﬁndings
(i) positive MPO-ANCA
(ii) elevated level of CRP
(iii) proteinuria and/or hematuria, or elevated levels of BUN and/or creatinine
(iv) chest X-ray ﬁndings: inﬁltration (pulmonary hemorrhage), and/or interstitial pneumonitis
(4) Diagnosis
(i) Deﬁnite
(a) At least two clinical manifestations with the histological ﬁndings
(b) At least two clinical manifestations including items (i) or (ii), and positive MPO-ANCA
(ii) Probable
(a) At least three clinical manifestations




(iii) allergic granulomatous angiits (Churg-Strauss syndrome)
(iv) Goodpasture syndrome
a comparison of clinical ﬁndings of MPA in the French
Vasculitis Study Group reported by Guillevin et al. [4]
and the Japanese Nationwide Epidemiological Survey [19]
reported by Hashimoto et al. The observed diﬀerences might
be expected because the same diagnostic criteria were not
used,althoughtheinclusioncriteriaforthediagnosisofMPA
werealmostthesame.Table 2 showsthediagnosticcriteriaof
MPA used in the Japanese Nationwide Epidemiological Sur-
vey. Interestingly, the female:male sex ratio was 1.23 in the
Frenchstudy,whichcontrastswith0.43intheJapanesestudy,
although the mean age at diagnosis was almost the same.
The incidence of clinical manifestations including fever and
weight loss in the French study was greater than that in the
Japanesestudy,buttheincidencesofarthralgiasandmyalgias
were almost the same. Concerning visceral involvement,
the incidence of renal involvement and lung involvement,
such as alveolar hemorrhage, pneumonitis, and pleuritis,
in the Japanese study was greater than that in the French
study; in contrast, the incidence of mononeuritis multiplex,
central nervous system involvement, and gastrointestinal
tract involvement in the French study was greater than that
in the Japanese study. The frequencies of hypertension were
34.1% in the French study and 41.3% in the Japanese study.
In the French study, ANCA was present in 74.5% of
patients, of whom 86.8% had pANCA and the remainder
had cANCA. In the Japanese study, pANCA was present in
90.4% of patients and cANCA was present in 9.6%. Among
pathological ﬁndings in the Japanese study, necrotizing
vasculitis was present in 32 out of 55 patients and crescentic
glomerulonephritis was present in 41 out of 47 patients (not
indicated in the French study). In the Japanese study, most
of the patients were treated with corticosteroids (93.4%) and
immunosuppressant drugs (71.0%). The mortality rate was
12.9% and the most frequent cause of death was infection
(36.5%) followed by alveolar hemorrhage (17.3) and renal
failure (13.5%). Guillevin et al. [4] noted that in the French
study, deaths were less frequent when patients had been
treated with corticosteroids and immunosuppressive drugs,
but relapse of MPA was common.
4.AAV inSSc
SSc is divided into two major clinical subsets, namely
diﬀuse cutaneous and limited cutaneous disease, which are
distinguished from one another primarily by the degree
and extent of skin involvement [20]. Overlap syndrome,
which has either diﬀuse or limited cutaneous disease
and typical features of one or more of other connective
tissue diseases, is also present [1]. Since the identiﬁ-
cation of antitopoisomerase-I (anti-Scl-70 antibody) and
anticentromere antibodies, it has been well known that
antitopoisomerase-1 antibodies are associated with diﬀuse
cutaneous disease as well as evident renal involvement
and pulmonary interstitial ﬁbrosis, and anticentromere
antibodies are associated with limited cutaneous disease as4 International Journal of Rheumatology
well as pulmonary hypertension. Anti-U1RNP and anti-Ku
antibodies are observed in patients with overlap syndrome
of SSc and myositis. Although the number of cases with
overlap syndrome of SSc and MPA among the cases of
SSc with AAV that have been reported is unknown, several
cases of overlap syndrome were suggested to be present
by Rho et al. [21] who analyzed and reviewed the clinical
characteristics of SSc with AAV in 50 cases reported in 31
articles. In this study, MPO-ANCA was the predominant
type (72%), but PR-3 ANCA was also found in some cases
(24%). The authors noted that 33 out of 50 cases had deﬁnite
features of AAV with pathological or clinical evidence
including crescentic glomerulonephritis, RPGN, pulmonary
hemorrhage, skin and/or nerve vasculitis, and necrotizing
vasculitis of muscle. High levels of inﬂammatory activity,
such as high ESR or CRP, or abnormal urinary sediments,
were also indicated. Cases with MPO-ANCA had a higher
prevalence of renal impairment and pulmonary hemorrhage
than those with PR-3 ANCA. Having antitopoisomerase-
1 antibodies made the development of AAV in SSc three
times more likely than that in patients who had neither
antibody. The mortality rate was 39.4% with virtually all
of the deaths occurring within 1 year. The major causes
of deaths included infection or septic shock, pulmonary
hemorrhage, intracerebral hemorrhage due to coagulopathy,
and acute cardiac failure. These ﬁndings strongly suggest the
coexistence of MPA and strongly contrast with the survival
rates and causes of deaths that are generally recorded for
patients with SSc.
Although the association of normotensive rapid renal
failure and MPO-ANCA that suggested the existence of a
renal speciﬁc subset apart from scleroderma renal crisis was
noted [13], nearly one-third of the MPA patients with renal
involvementwerehypertensive[4,19],andhypertensionwas
not an essential concomitant of renal failure due to SSc even
though renal arterial stenosis was observed pathologically
in SSc [22]. Blood pressure measurement cannot indicate
whether or not scleroderma renal crisis or RPGN associated
with AAV exists. However, the association of normotensive
renal failure with microangiopathic hemolytic anemia in
SSc was indicated [23]. When rapid renal failure or RPGN
with active urine sediments or systemic inﬂammatory man-
ifestations is observed in patients with SSc, the possibility
of MPA should always be considered. In these cases, a
renal biopsy should be considered to evaluate histological
ﬁndings because the use of basic laboratory indicators,
such as hematuria, proteinuria, or serum creatinine level,
is considerably limited in facilitating the prediction of the
site aﬀected by vasculitis [2, 4, 24]. The characteristic renal
histopathological ﬁndings of MPA are pauci-immune necro-
tizing and/or crescentic focal necrotizing glomerulonephritis
as well as small vessel arteritis, which is identical to the
lesions seen in WG or renal-limited vasculitis, which is a
subtype of MPA [6, 9]. However, this ﬁnding distinguishes
the disease from polyarteritis nodosa and SSc with fulmi-
nating course of malignant hypertension in which mucoid
thickening of proximal interlobular arteries and ﬁbrinoid
necrosis in distal interlobular arterioles are speciﬁc for
SSc [25].






digital ischemia + −
skin ulcers ++







honeycomb lung + −











CNS vasculitis − +
Histological ﬁndings;
ﬁbrinoid necrosis arteries, arterioles capillaries, arterioles





RPGN: rapidly progressive glomerulonephritis
CNS: central nervous system
pFNCGN: pauci-immune focal necrotizing crescentic glomerulonephritis.
Mortality is greatest in the setting of pulmonary-renal
syndrome in MPA. Pulmonary lesion is a small-vessel
vasculitis, with ﬁbrinoid necrosis of capillaries, leading
to alveolar septal disruption, blood-ﬁlled alveoli, and the
clinical sequelae of dyspnea, cough, and/or hemoptysis. The
relative risk of death in MPA has been calculated to be
8 times higher in patients with pulmonary hemorrhage
[26]. On the other hand, pulmonary hypertension, which is
mostly observed in limited cutaneous scleroderma, is rare in
MPA, although a few cases with WG and MPA accompanied
with pulmonary hypertension have been reported [27]. In
SSc, interstitial ﬁbrosis was found to be the most common
pulmonary lesion, showing bilateral ﬁbrosis of lower lung or
honeycomb lung in chest X-ray. Its presence correlated well
with clinical measurements of restrictive lung disease and
decreaseddiﬀusingcapacity.Arteriolarthickening, described
as medial hypertrophy or concentric intimal proliferation,
was the most speciﬁc lesion in lungs, being noted in 29%
of SSc patients in autopsy cases [22]. The diﬀerences in
vascular clinical ﬁndings between SSc and MPA are shown in
Table 3.International Journal of Rheumatology 5
No treatment for SSc is proven to be eﬀective in prevent-
ing progression of disease, reversing ﬁbrosis, or improving
long-term outcome, although a number of novel agents
including anti-interleukin-6, transforming growth factor-β-
directed therapies, and other novel biological agents are
being developed [28]. However, if SSc patients with MPA
have life-threatening visceral involvement such as rapid renal
failure or RPGN and pulmonary hemorrhage, the patients
should be treated with induction therapy using cyclophos-
phamide, methotrexate, corticosteroids, or plasmapheresis,
and so forth, according to disease severity soon after the
diagnosis of MPA, although attention should be paid to
reducing treatment toxicity [29].
5.Signiﬁcanceof MPO-ANCA inOverlap
Syndrome of MPA andSSc
The etiology of MPA is unknown, but is generally considered
to be the result of an interaction between triggering agents
and disease susceptibility genes. In primary AAV, MPO-
ANCAaswellasPR3-ANCAhasbeenestablishedasamarker
for diagnosis and has been implicated in the pathogenesis
of vasculitis [2, 30]. In most patients with MPA and/or
SSc with AAV, high titers of MPO-ANCA are associated
with disease activity, rises in MPO-ANCA titers precede
relapses, and even a case of MPO-ANCA seroconversion
associated with fulminant vasculitis in antitopoisomerase-
1 antibody positive SSc has been reported [31], but MPO-
ANCA titers do not necessarily correlate with disease activity
or vasculitis syndrome. There are also the cases without
clinical manifestations related to AAV in spite of MPO-
ANCA positivity. The same can be seen for other autoanti-
bodies, such as anti-U1-RNP antibodies, antiphospholipid
antibodies, and rheumatoid factor, in rheumatic diseases.
Althoughthereasonforcaseswithoutclinicalmanifestations
showing MPO-ANCA positivity is not known, the following
reasons may be considered: (1) it is a predictive marker
for the development of AAV in the future, (2) it is an
epiphenomenon, and (3) false positivity. The pathogenic
potential of MPO-ANCA to small-vessel vasculitis may be
due to not only quantities but also qualities of MPO-
ANCA such as immunoglobulin phenotypes, aﬃnity and/or
avidity of MPO-ANCA, and speciﬁc risk epitope for
MPO-ANCA.
Concerning the source of antigens, attention has been
focused on neutrophil extracellular traps (NETs)[32], which
are chromatin ﬁbers and are released by ANCA-stimulated
neutrophils and contain the targeted autoantigens of PR3
and MPO [33] as well as topoisomerase-1. This may
be circumstantial evidence that antitopoisomerase-1 anti-
bodies occur more frequently in SSc with AAV than
are usually found in SSc as described in the paper of
Rho et al. [21].
Some investigators pointed out that ANCA positivity in
SSc is a red ﬂag and draws attention [17, 21]. This is true,
and it is important not to overlook characteristic clinical
manifestations of AAV during the course of the disease in
SSc.
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